Related references
Note: Only part of the references are listed.Incidence of brain metastases in renal cell carcinoma treated with sorafenib
C. Massard et al.
ANNALS OF ONCOLOGY (2010)
Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature
Dan-Fang Yan et al.
BMC CANCER (2010)
Safety and Efficacy Results of the Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America
Walter M. Stadler et al.
CANCER (2010)
Bevacizumab Safety in Patients with Central Nervous System Metastases
Benjamin Besse et al.
CLINICAL CANCER RESEARCH (2010)
A 4-Week Intrathecal Toxicity and Pharmacokinetic Study With Trastuzumab in Cynomolgus Monkeys
Angelique P. J. M. Braen et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2010)
The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics
Jeffrey J. Olson et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
Laurie E. Gaspar et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
Minesh P. Mehta et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
Mark E. Linskey et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
Steven N. Kalkanis et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Safety of Bevacizumab in Patients With Non-Small-Cell Lung Cancer and Brain Metastases
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases
Brian Leyland-Jones
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin E. Gore et al.
LANCET ONCOLOGY (2009)
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis
Jeong-Eun Kim et al.
LUNG CANCER (2009)
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population
Shenglin Ma et al.
LUNG CANCER (2009)
Erlotinib and nonsmall cell lung cancer with brain metastases: A case study with a complete and prolonged response over 17 months
A. Mairovitz et al.
REVUE DE PNEUMOLOGIE CLINIQUE (2009)
Extended survival in women with brain Metastases from HER2 overexpressing breast cancer
David N. Church et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Defining prognosis for women with breast cancer and CNS metastases by HER2 status
S. Dawood et al.
ANNALS OF ONCOLOGY (2008)
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report
Hans-Joachim Stemmler et al.
ANTI-CANCER DRUGS (2008)
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases
Giuseppe Altavilla et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain
Brunilde Gril et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Eligibility of patients with brain metastases for phase I trials: time for a rethink?
Craig P. Carden et al.
LANCET ONCOLOGY (2008)
What is the risk of intracranial bleeding during anti-VEGF therapy?
Craig P. Carden et al.
NEURO-ONCOLOGY (2008)
Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: Two case reports
Joachim von Pawel et al.
ONKOLOGIE (2008)
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer:: the dark side of the moon?: A meta-analysis of the randomized trials
Emilio Bria et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) disposition and drug interactions
Joseph W. Polli et al.
DRUG METABOLISM AND DISPOSITION (2008)
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer
Rupert Bartsch et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
Mary C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain
Chi Wu et al.
LUNG CANCER (2007)
Trastuzumab treatment and the risk of central nervous system (CNS) metastases
M. C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Recurrent responses to non-small cell lung cancer brain metastases with erlotinib
Sanjay Popat et al.
LUNG CANCER (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
HER-2 overexpressed breast cancer and brain metastases
M. Lichinitser et al.
BREAST (2007)
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
Hans-Joachim Stemmler et al.
ANTI-CANCER DRUGS (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer
Zsolt Gabos et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effect of gefitinib on brain metastases from non-small cell lung cancer - Two case reports
Noriyuki Nishi et al.
NEUROLOGIA MEDICO-CHIRURGICA (2006)
Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption
Manabu Kinoshita et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
BC Pestalozzi et al.
ANNALS OF ONCOLOGY (2006)
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
H. J. Stemmler et al.
BREAST (2006)
Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
T Yau et al.
ACTA ONCOLOGICA (2006)
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status
John Souglakos et al.
BREAST CANCER RESEARCH (2006)
Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report
HJ Stemmler et al.
ANTI-CANCER DRUGS (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Current management of brain metastases, with a focus on systemic options
CJ Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Monoclonal antibodies as therapeutic agents for cancer
M Harris
LANCET ONCOLOGY (2004)
Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment
E Shmueli et al.
EUROPEAN JOURNAL OF CANCER (2004)
Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results
M Baumann et al.
RADIOTHERAPY AND ONCOLOGY (2004)
Gefitinib in patients with brain metastases from non-small-cell lung cancer:: a prospective trial
GL Ceresoli et al.
ANNALS OF ONCOLOGY (2004)
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer
K Hotta et al.
LUNG CANCER (2004)
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
KD Miller et al.
ANNALS OF ONCOLOGY (2003)
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
JC Bendell et al.
CANCER (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
J Albanell et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The diagnosis and management of brain metastases
MJ van den Bent
CURRENT OPINION IN NEUROLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
